Bristol Myers' RYZ101 and Admilparant Hit Phase 3 Goals, Stock Rises 2.2%
BMY sits 35% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb reported two late-stage trial wins on Monday. RYZ101, a radiopharmaceutical acquired via the $4.1B RayzeBio deal, significantly improved progression-free survival in a Phase 3 trial for rare advanced GI and pancreatic tumors. Separately, a 60mg dose of admilparant met its primary endpoint in a Phase 3 idiopathic pulmonary fibrosis trial, while the 120mg dose did not. The stock rose 2.2%, snapping a two-day losing streak. These readouts come as BMY faces a 2028 patent cliff for Opdivo and Eliquis, making pipeline success critical. The RYZ101 data validates the RayzeBio acquisition and strengthens the oncology franchise; admilparant's mixed dose results still offer a path forward in IPF. Next watch: full data presentations and potential regulatory filings for both programs.
At the time of this announcement, BMY was trading at $57.21 on NYSE in the Life Sciences sector, with a market capitalization of approximately $116.9B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.